Kane Biotech (CVE:KNE) Stock Price Up 9.1% – Should You Buy?

Shares of Kane Biotech Inc. (CVE:KNE) were up 9.1% during mid-day trading on Tuesday . The company traded as high as C$0.13 and last traded at C$0.12. Approximately 243,500 shares traded hands during mid-day trading, an increase of 90% from the average daily volume of 127,871 shares. The stock had previously closed at C$0.11.

Kane Biotech Trading Up 4.2 %

The firm has a market capitalization of C$16.56 million, a PE ratio of -4.17 and a beta of 0.52. The company’s 50-day moving average price is C$0.13 and its 200-day moving average price is C$0.14. The company has a debt-to-equity ratio of 1,164.24, a quick ratio of 0.39 and a current ratio of 0.82.

Kane Biotech (CVE:KNE) last posted its quarterly earnings results on Thursday, August 29th. The company reported C($0.01) earnings per share (EPS) for the quarter. The company had revenue of C$0.62 million for the quarter.

Kane Biotech Company Profile

Kane Biotech Inc, a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, an antimicrobial wound gel platform; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine for treating wounds and otic infections.